Please try another search
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab, which is in phase 2 clinical trial for indications of solid tumors; and in phase 1 clinical trial for indications of acute myeloid leukemia and myelodysplastic syndromes. In addition, it develops interferon beta-1a to prevent toxicities from CAR-T therapy in phase 2 clinical trial; and AOC3 inhibitor, which is in preclinical studies for indications of chemotherapy-induced neutropenia. Further, it develops Haematokine, an investigational AOC3 protein inhibitor that is used for regenerative medicines in hematological malignancies, as well as chemotherapy induced suppression of the bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
Name | Age | Since | Title |
---|---|---|---|
Tuomo Patsi | 60 | 2023 | Independent Non-Executive Chairman |
Jonathan Kenneth Charles Knowles | 77 | 2015 | Chairman of the Scientific Advisory Board |
Markku Tapani Jalkanen | 70 | 2006 | Founder & Executive Director |
Huaizheng Peng | 62 | 2015 | Board Observer |
Sirpa Jalkanen | 70 | 2019 | Member of the Scientific Advisory Board |
John Poulos | 70 | 2017 | Independent Non-Executive Director |
Christophe Massard | - | 2019 | Member of the Scientific Advisory Board |
David Adams | - | 2019 | Member of the Scientific Advisory Board |
Tyler Curiel | - | 2021 | Member of the Scientific Advisory Board |
Marie-Louise Helena Fjallskog | 60 | 2022 | Independent Non-Executive Director |
Christine Ann Roth | 61 | 2023 | Independent Non-Executive Director |
Juho Markku Jalkanen | 46 | 2017 | Founder, CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review